alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

28,580 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 26–50 of 143 studies in Digital health tools of type cohort or longitudinal study (page 2 of 6) · 28,580 in the whole library · How the 0–100 score works

Download bibliography of these 143 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Other subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 14,058 studies have no institution on record and are not counted here.

What “Digital health tools” covers

Digital health tools — Apps, wearables, online tests and other technology used to detect, monitor or support people with dementia.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Increased CSF neurogranin concentration is specific to Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 66 out of 100. Neurology 2016-01-29

An optimized immunoassay was used to analyze CSF Ng in a retrospective cohort of 331 participants with different neurodegenerative diseases, including healthy controls (n = 19), biomarker-proven Alzheimer disease (AD) (n = 100), genetic AD (n = 2), behavioral variant frontotemporal dementia (n = 20), speech variant frontotemporal dementia (n = 21), Lewy body dementia (n = 13), Parkinson disease (n = 31), progressive supranuclear palsy (n = 46), multiple system atrophy (n = 29), as well as a heterogeneous group with non-neurodegenerative cognitive impairment (n = 50). 1 key finding →

Design: retrospective cohort Participants: 19 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Performance of Machine Learning Algorithms for Predicting Progression to Dementia in Memory Clinic Patients

✓ Peer-reviewed alzhub usefulness score 66 out of 100. JAMA network open 2021-12-01

These findings suggest that machine learning algorithms could accurately predict incident dementia within 2 years in patients receiving care at memory clinics using only 6 variables. 5 key findings →

Design: prospective cohort Participants: 307 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Predicting cognitive decline with deep learning of brain metabolism and amyloid imaging

✓ Peer-reviewed alzhub usefulness score 66 out of 100. Behavioural brain research 2018-02-14

For effective treatment of Alzheimer's disease (AD), it is important to identify subjects who are most likely to exhibit rapid cognitive decline. 3 key findings →

Design: longitudinal study Participants: 139 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Low-Value Care at the Actionable Level of Individual Health Systems

✓ Peer-reviewed alzhub usefulness score 66 out of 100. JAMA internal medicine 2021-11-01

The findings of this large cohort study suggest that system-level measurement and reporting of specific low-value services is feasible, enables cross-system comparisons, and reveals a broad range of low-value care use. 3 key findings →

Design: cohort study Evidence: moderate

Full summary, score breakdown and related studies → Original source

Association of dementia with early rehospitalization among Medicare beneficiaries

✓ Peer-reviewed alzhub usefulness score 66 out of 100. Archives of gerontology and geriatrics 2014-03-11

Preventable hospital readmissions have been recognized as indicators of hospital quality, a source of increased healthcare expenditures, and a burden for patients, families, and caregivers. 2 key findings →

Design: cohort study Participants: 5,133 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Equitability of Depression Screening After Implementation of General Adult Screening in Primary Care

✓ Peer-reviewed alzhub usefulness score 66 out of 100. JAMA network open 2022-08-01

Men, racial and ethnic minority individuals, older adults, and those with language barriers are at increased risk for undertreatment of depression. 5 key findings →

Design: cohort study Evidence: moderate

Full summary, score breakdown and related studies → Original source

Neuropsychiatric Ramifications of Severe COVID-19 and Other Severe Acute Respiratory Infections

✓ Peer-reviewed alzhub usefulness score 66 out of 100. JAMA psychiatry 2022-07-01

In this cohort study of data from 8.38 million adults (4.18 million women, 4.20 million men; mean [SD] age 49.18 [18.45] years); 16 679 (0.02%) survived a hospital admission for SARI, and 32 525 (0.03%) survived a hospital admission for COVID-19. 4 key findings →

Design: cohort study Evidence: moderate

Full summary, score breakdown and related studies → Original source

Is Cancer Protective for Subsequent Alzheimer's Disease Risk? Evidence From the Utah Population Database

✓ Peer-reviewed alzhub usefulness score 66 out of 100. The journals of gerontology. Series B, Psychological sciences and social sciences 2017-10-01

Careful consideration of model specification and the profound effects of mortality selection in the older adult population is essential when investigating the relationship between aging-related diseases such as cancer and AD. 4 key findings →

Design: cohort study Participants: 92,425 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Machine Learning to Develop and Internally Validate a Predictive Model for Post-operative Delirium in a Prospective, Observational Clinical Cohort Study of Older Surgical Patients

✓ Peer-reviewed alzhub usefulness score 65 out of 100. Journal of general internal medicine 2020-10-19

We developed machine learning prediction models for post-operative delirium that performed better than chance and are comparable with traditional stepwise logistic regression. 1 key finding →

Design: cohort study Participants: 134 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Plasma metabolic profiles predict future dementia and dementia subtypes: a prospective analysis of 274,160 participants

✓ Peer-reviewed alzhub usefulness score 65 out of 100. Alzheimer's research & therapy 2024-01-22

We conducted the largest metabolome investigation of dementia to date, for the first time revealed the metabolite importance ranking, and highlighted the contribution of plasma metabolites for dementia prediction. 5 key findings →

Design: longitudinal study Participants: 274,160 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Association Between Hormone-Modulating Breast Cancer Therapies and Incidence of Neurodegenerative Outcomes for Women With Breast Cancer

✓ Peer-reviewed alzhub usefulness score 64 out of 100. JAMA network open 2020-03-02

Among patients with breast cancer, tamoxifen and steroidal aromatase inhibitors were associated with a decrease in the number who received a diagnosis of NDD, specifically Alzheimer disease and dementia. 4 key findings →

Design: cohort study Evidence: moderate

Full summary, score breakdown and related studies → Original source

Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings

✓ Peer-reviewed alzhub usefulness score 64 out of 100. Journal of managed care pharmacy : JMCP 2005-04-01

For the cohort of patients that remained on therapy > or =60 days, the mean time to treatment discontinuation was 331 days (95% confidence interval [CI], 307-355) for rivastigmine patients (n = 392) versus 337 days (95% CI, 322-352) for donepezil patients (n = 1288). 4 key findings →

Design: cohort study Participants: 392 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Connected speech as a marker of disease progression in autopsy-proven Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 63 out of 100. Brain : a journal of neurology 2013-10-18

Previous studies from our group have shown that language changes may be reflected in connected speech production in the earliest stages of typical Alzheimer's disease. 3 key findings →

Design: cohort study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

English Longitudinal Study of Aging: can Internet/E-mail use reduce cognitive decline?

✓ Peer-reviewed alzhub usefulness score 63 out of 100. The journals of gerontology. Series A, Biological sciences and medical sciences 2014-09-01

Digital literacy may help reduce cognitive decline among persons aged between 50 and 89 years. 2 key findings →

Design: longitudinal study Participants: 6,442 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Machine learning reveals distinct neuroanatomical signatures of cardiovascular and metabolic diseases in cognitively unimpaired individuals

✓ Peer-reviewed alzhub usefulness score 63 out of 100. Nature Communications 2025-03-19

Comorbid cardiovascular and metabolic risk factors (CVM) differentially impact brain structure and increase dementia risk, but their specific magnetic resonance imaging signatures (MRI) remain poorly characterized. 1 key finding →

Design: cohort study Participants: 37,096 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 62 out of 100. Molecular neurodegeneration 2020-09-22

Subjective cognitive decline (SCD) is regarded as the first clinical manifestation in the Alzheimer's disease (AD) continuum. 3 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Healthy brain connectivity predicts atrophy progression in non-fluent variant of primary progressive aphasia

✓ Peer-reviewed alzhub usefulness score 62 out of 100. Brain : a journal of neurology 2016-08-06

Graph theoretical analysis of the speech/language network showed that regions with shorter functional paths to the epicentre exhibited greater longitudinal atrophy. 4 key findings →

Design: longitudinal study Participants: 30 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

The tauopathy associated with mutation +3 in intron 10 of Tau: characterization of the MSTD family

✓ Peer-reviewed alzhub usefulness score 62 out of 100. Brain : a journal of neurology 2007-12-07

Multiple system tauopathy with presenile dementia (MSTD) is an inherited disease caused by a (g) to (a) transition at position +3 in intron 10 of Tau. 1 key finding →

Design: longitudinal study Participants: 21 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Glycemic and lipid variability for predicting complications and mortality in diabetes mellitus using machine learning

✓ Peer-reviewed alzhub usefulness score 62 out of 100. BMC endocrine disorders 2021-05-04

The study consists of 25,186 patients (mean age = 63.0, interquartile range [IQR] of age = 15.1 years, male = 50%). 3 key findings →

Design: cohort study Participants: 25,186 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Neuropathological fingerprints of survival, atrophy and language in primary progressive aphasia

✓ Peer-reviewed alzhub usefulness score 62 out of 100. Brain : a journal of neurology 2022-06-01

Comparisons of ADNC in typical amnestic versus atypical aphasic dementia and of TDP in type A versus type C revealed fundamental biological and clinical differences, suggesting that members of each pair may constitute distinct clinicopathologic entities despite identical downstream proteinopathies. 1 key finding →

Design: longitudinal study Participants: 68 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 28,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,580 records, built mostly from automated pulls of Europe PMC (62.2% of the library) and OpenAlex (17.8%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.6% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed